FLU SHOTS WITH SQUALENE [AKA MF59] ON THE WAY FOR U.S.

[Guest guest]

Comment from Dr. Tenpenny [OsteoMed II]:>>COMMENT: Novartis and the FDA are setting things in place to approve flu shots with MF59 to be used in the US next year. The factory is built; they need a return on the investment. This is a looming disaster for Americans in the years to come. And at the same time they are pushing shots with adjuvants in the US, Switzerland's medical regulator has recommended patients with serious autoimmune diseases to avoid H1N1 flu vaccines from Novartis, due to little research and high risk of autoimmune disease.<<==========http://www.reuters.com/article/idUSN2017059420100120UPDATE 1-Novartis flu vaccine additive boosts wide protectionWed Jan 20, 2010 1:02pm ESTRelated News Swiss warn on flu vaccine with autoimmune disease Wed, Jan 20 2010 Experts identify key triggers in malaria vaccine hunt Tue, Jan 19 2010 REFILE-Serbia halts purchases of flu A/H1N1 vaccines Tue, Jan 12 2010 UPDATE 1-SciClone says adjuvant raises H1N1 vaccine response Tue, Jan 12 2010 SciClone says adjuvant raises H1N1 vaccine response; shares up Tue, Jan 12 2010 (Updates throughout with quotes and details)* Adjuvants provide wide flu response* Might help protect against mutant versions of virusBy Maggie Fox, Health and Science EditorWASHINGTON, Jan 20 (Reuters) - A vaccine additive made by Novartis (NOVN.VX) and used in its European influenza shots can boost the body's immune response to a wide range of viruses, U.S. researchers reported on Wednesday.Tests in the laboratory suggested the so-called adjuvant, called MF59, helped the immune system counteract not only the H5N1 virus in the current experimental bird flu vaccine, but mutant viruses as well.The U.S. Food and Drug Administration study, published in the journal Science Translational Medicine, suggests using vaccines with adjuvants may protect patients against even more types of flu viruses than they are being vaccinated against."MF59 adjuvant improves the immune response to a H5N1 vaccine by inducing qualitative and quantitative expansion of the antibody repertoires with protective potential," Hana Golding of the U.S. Food and Drug Administration and colleagues wrote.Adjuvants, often as simple as an oil and water mixture, broaden the body's response to a vaccine, reducing the amount of active ingredient called antigen needed.Influenza viruses are highly mutation-prone and people must be vaccinated against the particular strains circulating. This year, governments and companies had to formulate new vaccines against the new pandemic H1N1 swine flu and give them alongside vaccines for seasonal influenza.And seasonal influenza immunizations must be reformulated every year because the viruses "drift," or mutate slightly.Researchers are also testing vaccines against H5N1 bird flu, which has only infected a few hundred people but which doctors fear could cause a new pandemic.Swine flu has killed at least 14,000 people globally and while it is on the wane, health officials are still urging people to be vaccinated against it in case it mutates and comes back in a more deadly form.Adjuvants are widely used in European flu vaccines as well as in Canada. But are not widely used in the United States -- even though the federal government has spent nearly $700 million buying them.The reason? People might not trust them.Other studies have shown adjuvants can stretch the supply of flu vaccine, because shots using them require much less of the actual vaccine antigen."Adjuvanted vaccines produce higher immune response than unadjuvanted vaccines particularly in the elderly and young children," Dr. Vas Narasimhan, president of Novartis Vaccines USA, told a U.S. Congressional hearing last November.The National Institute of Allergy and Infectious Diseases has awarded $60 million to researchers and companies to develop new adjuvants. =====In accordance with Title 17 U.S.C. Section 107, this material is distributed without profit to those who have expressed a prior interest in receiving the included information for research and educational purposes.

[Guest guest]

And the excess vaccines have been pushed on Costa Rica---where they have made it compulsory--even though it is admitted that the pandemic was a fairy tale---and there is no H1H1 flu in sight....go figure....--- On Mon, 1/25/10, Viviane Lerner <vivlerner wrote:

Viviane Lerner <vivlerner FLU SHOTS WITH SQUALENE [AKA MF59] ON THE WAY FOR U.S."*VACCINE TRUTH" <Vaccinetruth >Cc: "NATURAL NEWS" <insider, "TETRAHEDRON" <sherrikane, "HEALTH & HEALING" , "IMVA" <director, "ALTERNET" <joshua.hollandReceived: Monday, January 25, 2010, 12:10 AM

 

Comment from Dr. Tenpenny [OsteoMed II]:

>>COMMENT: Novartis and the FDA are setting things in place to approve flu shots with MF59 to be used in the US next year. The factory is built; they need a return on the investment. This is a looming disaster for Americans in the years to come.

 

And at the same time they are pushing shots with adjuvants in the US, Switzerland' s medical regulator has recommended patients with serious autoimmune diseases to avoid H1N1 flu vaccines from Novartis, due to little research and high risk of autoimmune disease.<<

==========

http://www.reuters. com/article/ idUSN20170594201 00120

 

UPDATE 1-Novartis flu vaccine additive boosts wide protection

Wed Jan 20, 2010 1:02pm EST

 

Related News

 

Swiss warn on flu vaccine with autoimmune disease

Wed, Jan 20 2010

Experts identify key triggers in malaria vaccine hunt

Tue, Jan 19 2010

REFILE-Serbia halts purchases of flu A/H1N1 vaccines

Tue, Jan 12 2010

UPDATE 1-SciClone says adjuvant raises H1N1 vaccine response

Tue, Jan 12 2010

SciClone says adjuvant raises H1N1 vaccine response; shares up

Tue, Jan 12 2010

 

(Updates throughout with quotes and details)

* Adjuvants provide wide flu response

* Might help protect against mutant versions of virus

By Maggie Fox, Health and Science Editor

WASHINGTON, Jan 20 (Reuters) - A vaccine additive made by Novartis (NOVN.VX) and used in its European influenza shots can boost the body's immune response to a wide range of viruses, U.S. researchers reported on Wednesday.

Tests in the laboratory suggested the so-called adjuvant, called MF59, helped the immune system counteract not only the H5N1 virus in the current experimental bird flu vaccine, but mutant viruses as well.

The U.S. Food and Drug Administration study, published in the journal Science Translational Medicine, suggests using vaccines with adjuvants may protect patients against even more types of flu viruses than they are being vaccinated against.

"MF59 adjuvant improves the immune response to a H5N1 vaccine by inducing qualitative and quantitative expansion of the antibody repertoires with protective potential," Hana Golding of the U.S. Food and Drug Administration and colleagues wrote.

Adjuvants, often as simple as an oil and water mixture, broaden the body's response to a vaccine, reducing the amount of active ingredient called antigen needed.

Influenza viruses are highly mutation-prone and people must be vaccinated against the particular strains circulating. This year, governments and companies had to formulate new vaccines against the new pandemic H1N1 swine flu and give them alongside vaccines for seasonal influenza.

And seasonal influenza immunizations must be reformulated every year because the viruses "drift," or mutate slightly.

Researchers are also testing vaccines against H5N1 bird flu, which has only infected a few hundred people but which doctors fear could cause a new pandemic.

Swine flu has killed at least 14,000 people globally and while it is on the wane, health officials are still urging people to be vaccinated against it in case it mutates and comes back in a more deadly form.

Adjuvants are widely used in European flu vaccines as well as in Canada. But are not widely used in the United States -- even though the federal government has spent nearly $700 million buying them.

The reason? People might not trust them.

Other studies have shown adjuvants can stretch the supply of flu vaccine, because shots using them require much less of the actual vaccine antigen.

"Adjuvanted vaccines produce higher immune response than unadjuvanted vaccines particularly in the elderly and young children," Dr. Vas Narasimhan, president of Novartis Vaccines USA, told a U.S. Congressional hearing last November.

The National Institute of Allergy and Infectious Diseases has awarded $60 million to researchers and companies to develop new adjuvants.

 

 

=====

In accordance with Title 17 U.S.C. Section 107, this material is distributed without profit to those who have expressed a prior interest in receiving the included information for research and educational purposes.

Make your browsing faster, safer, and easier with the new Internet Explorer® 8. Optimized for Get it Now for Free!